

Amendments to the Claims:



Listing of Claims:

Claim 1 (original): Microparticles comprising a somatostatin analogue comprising the amino acid sequence of formula I




I

wherein X_1 is a radical of formula (a) or (b)




wherein R_1 is optionally substituted phenyl,

R_2 is $-\text{Z}_1-\text{CH}_2-\text{R}_1$, $-\text{CH}_2-\text{CO}-\text{O}-\text{CH}_2-\text{R}_1$,



or




wherein Z_1 is O or S, and

X_2 is an α -amino acid having an aromatic residue on the C_α side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys⁹ of the native somatostatin-14

in free form, salt form, or protected form,
embedded in a polymer matrix.

Claim 2 (original): Microparticles according to claim 1 wherein the somatostatin analogue is a compound of formula III



III

wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and
wherein R is NR₁R₂-C₂₋₆alkylene or guanidine-C₂₋₆alkylene, and each of R₁ and R₂
independently is H or C₁₋₄alkyl,
in free form, salt form or protected form.

Claim 3 (currently amended): Microparticles according to claim 1 ~~or 2~~ wherein the
somatostatin analogue is in pamoate salt form.

Claim 4 (currently amended): Microparticles according to ~~any preceding~~ claim 1
wherein the polymer matrix comprises a linear or branched polylactide-co-glycolide.

Claim 5 (currently amended): Microparticles according to ~~any preceding~~ claim 1
wherein the polymeric matrix comprises at least two different polymers.

Claim 6 (currently amended): Microparticles according to ~~any preceding~~ claim 1
further comprising a surfactant, a porosity influencing agent and/or a basic salt.

Claim 7 (currently amended): A pharmaceutical composition comprising
microparticles of ~~any preceding~~ claim 1 and a water-based vehicle comprising a wetting
agent.

Claim 8 (original): A composition according to claim 7 wherein the wetting agent
comprises a poloxamer and/or a polyoxyethylene-sorbitan-fatty acid ester.

Claim 9 (currently amended): A composition according to ~~any one of claims 7 or~~
8 claim 7 wherein the vehicle comprises a tonicity agent.

Claim 10 (currently amended): A composition according to ~~any one of claims 7 or~~
8 claim 7 wherein the vehicle comprises a viscosity increasing agent.

Claim 11 (currently amended): A kit comprising microparticles according to ~~any one~~
~~of claims 1 to 6~~ claim 1 and a water-based vehicle.

Claim 12 Canceled.

Claim 13 (currently amended): A method of treating a disease or disorder with an
aetiology comprising or associated with excess GH- and/or IGF-1 secretion in a subject in
need thereof which comprises administering microparticles according to claim 1 ~~any one of~~
~~claims 1 to 6 or of a pharmaceutical composition according to any one of claims 7 to 10 to~~
~~the subject.~~